Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Poolbeg Pharma Ltd. ( (GB:POLB) ) has shared an update.
Poolbeg Pharma plc has successfully raised £4.715 million through an oversubscribed placing and subscription, reflecting strong investor demand. The funds will support the company’s clinical trials, including the Phase 2a trial for POLB 001, aimed at preventing cancer immunotherapy-induced Cytokine Release Syndrome, and an oral GLP-1 proof-of-concept trial targeting the obesity market. These initiatives are expected to extend the company’s cash runway through 2027 and potentially unlock significant market opportunities, with POLB 001 alone targeting a market expected to exceed $10 billion.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide receptor (GLP-1R) agonist.
Average Trading Volume: 1,108,755
Technical Sentiment Signal: Sell
For detailed information about POLB stock, go to TipRanks’ Stock Analysis page.